Bulls Keep Del Fris...
Health Care: Drugs
Cyclacel Pharmaceuticals Inc. (CYCC: NASDAQ)
$3.04 0.04 | 1.33%
05/17/13 - 04:00 PM ET
Company Balance Sheet
| Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
| Assets | ||||
|---|---|---|---|---|
| Cash and Equivalents | 16.41M | 24.45M | 29.50M | 11.49M |
| Receivables | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventories | 0.00 | 182.00K | 174.00K | 145.00K |
| Other Current Assets | 861.00K | 0.00 | 0.00 | 0.00 |
| Total Current Assets | 18.87M | 25.83M | 31.05M | 13.37M |
| Property, Plant & Equipment, Gross | 7.71M | 8.37M | 8.39M | 10.03M |
| Accumulated Depreciation & Depletion | 7.58M | 8.20M | 7.98M | 9.13M |
| Property, Plant & Equipment, Net | 129.00K | 167.00K | 408.00K | 901.00K |
| Intangibles | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Non-Current Assets | 353.00K | 0.00 | 0.00 | 196.00K |
| Total Non-Current Assets | 482.00K | 167.00K | 408.00K | 1.10M |
| Liabilities & Shareholder Equity | ||||
| Total Assets | 19.35M | 26.00M | 31.46M | 14.47M |
| Accounts Payable | 2.26M | 1.76M | 1.72M | 3.16M |
| Short Term Debt | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Current Liabilities | 1.48M | 71.00K | 680.00K | 2.53M |
| Total Current Liabilities | 9.34M | 6.50M | 6.54M | 9.82M |
| Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 |
| Deferred Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Non-Current Liabilities | 0.00 | 0.00 | 0.00 | 0.00 |
| Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Non-Current Liabilities | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 9.34M | 6.50M | 6.54M | 9.82M |
| Preferred Stock Equity | 1.00K | 1.00K | 1.00K | 2.00K |
| Common Stock Equity | 10.02M | 19.50M | 24.92M | 4.64M |
| Common Par | 9.00K | 54.00K | 47.00K | 26.00K |
| Additional Paid In Capital | 280.21M | 276.45M | 266.67M | 226.88M |
| Cumulative Translation Adjustment | 0.00 | 0.00 | 0.00 | 0.00 |
| Retained Earnings | -270.25M | -257.06M | -241.82M | -222.28M |
| Treasury Stock | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Equity Adjustments | 48.00K | 57.00K | 31.00K | 20.00K |
| Total Capitalization | 10.02M | 19.50M | 24.92M | 4.64M |
| Total Equity | 10.02M | 19.50M | 24.92M | 4.64M |
| Total Liabilities & Stock Equity | 19.35M | 26.00M | 31.46M | 14.47M |
| Total Common Shares Outstanding | 8.69M | 7.75M | 6.65M | 3.68M |
| Preferred Shares | 1.21M | 1.21M | 1.21M | 2.05M |
| Treasury Shares | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic Weighted Shares Outstanding | 8.29M | 7.19M | 5.41M | 3.17M |
| Diluted Weighted Shares Outstanding | 8.29M | 7.19M | 5.41M | 3.17M |
| Number of Employees | 17 | 18 | 18 | 24 |
| Number of Part-Time Employees | 0 | 0 | 0 | 0 |
Portfolios with CYCC
- Portfolio NameUser Type
- ContributorEarnings Short Squeeze Play...
- ContributorStocks Under-$10 Moving Hig...
- ContributorBreakout Stocks Of The Week...
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Moving Hig...
- Uservlady 1
- Contributor13 Biotech Stocks Bought an...
- ProWilbur Ross - Invesco Priva...
- Contributor10 Cheap Biotech Stocks Tha...
- Userjeezlola
Latest CYCC Headlines from TheStreet
- Cyclacel Pharmaceuticals Announces $20 Million Underwritten Offering 05.16.13 | 09:05 am
- Cyclacel Pharmaceuticals Announces Proposed Public Offering Of Common Stock 05.15.13 | 04:05 pm
- Cyclacel Reports First Quarter 2013 Financial Results 05.13.13 | 04:05 pm
- Cyclacel Pharmaceuticals To Announce Release Of First Quarter 2013 Financial Results 05.10.13 | 07:05 am
- Cyclacel Reports Updated Phase 2 Survival Data Of Sapacitabine For MDS 04.30.13 | 07:04 am
- Cyclacel Pharmaceuticals To Present At The 12th Annual Needham Healthcare Conference 04.23.13 | 07:04 am
- Reminder: Cyclacel Pharmaceuticals' 6% Preferred Stock Goes Ex-Dividend Soon 04.16.13 | 01:04 pm
- Combination Potential Of Cyclacel's Sapacitabine And Seliciclib Reported At AACR 04.09.13 | 02:04 pm
- AACR Press Conference Highlights Combination Potential Of Two Cyclacel Drugs 04.08.13 | 07:04 am
- Cyclacel Announces Sale Of Four Cyclacel Romidepsin-Related Patents To Celgene And Dismissal Of All Claims In Their Patent Litigation 04.04.13 | 07:04 am
Press Releases for CYCC
Partner Headlines for CYCC
- Cyclacel Pharma to Offer New Sapacitabine Data at ASH on Dec. 9th - Benzinga 12.04.12 | 09:12 am
- Upcoming AML Treatments - Which Company Will Fly? - Seeking Alpha 12.03.12 | 09:12 am
- 4 Cash Loaded Biotech Stocks With Little Debt - Seeking Alpha 08.30.12 | 09:08 am
- Biotechnology Stocks To Watch Ahead Of ASCO 2012: Part 3 - Seeking Alpha 05.25.12 | 08:05 pm
- Cyclacel: An Intriguing Long Shot - Seeking Alpha 03.20.12 | 08:03 am
- Q3 Micro-Cap Biotech Picks By The World's Largest Fund Managers - Seeking Alpha 12.08.11 | 09:12 am
- Zacks #1 Rank Additions for Friday - Tale of the Tape - Zacks 11.18.11 | 09:11 am
- Buy And Sell Ideas Based On Wednesday's Big News And Price Decliners - Seeking Alpha 09.29.11 | 08:09 am
- The Biotech Bump: Cyclacel Pharmaceuticals - Benzinga 07.28.11 | 01:07 pm
- Profit From These 3 Analysts' Stock Picks for Under $10 - Seeking Alpha 07.13.11 | 09:07 am
